Therapeutic antibody development company Patrys (ASX:PAB) has announced new pre-clinical data for its lead asset, PAT-DX1, from a study conducted by Professor Terrence Johns of the Telethon Kids Cancer Centre.
The company said results from the study provide strong support for the continued development of PAT-DX1 in high-grade glioma (HGG). This is a fast-growing and clinically challenging form of brain cancer.
The study showed that combining a therapeutic dose of standard radiation therapy with a dose of PAT-DX1 increased median survival by 12 days compared to radiation treatment alone.
HGG is the most common and deadly type of brain cancer, affecting both adults and children. Adult patients have a five-year survival rate of 10 per cent with standard therapy (surgical resection, radiation and chemotherapy). In children, HGG is a rapid and universally lethal disease.
Patrys CEO and managing director Dr James Campbell said, “This is a very exciting result, showing a robust benefit from combining PAT-DX1 with standard of care radiation therapy in high-grade glioma, one of the most difficult-to-treat cancers.
"This, and additional studies funded under the auspices of Cure Brain Foundations’ Clinical Accelerator program, of which our collaborator Professor Johns was the inaugural recipient, will guide us towards optimised therapeutic regimes and timing schedules as we progress PAT-DX1 into the clinic. Having successfully completed our engineering run for PAT-DX1 recently we are well positioned to advance towards the clinic, and excited by the potential of this novel and exciting agent.”
Professor Terrance Johns addedd, “It is exciting for us to see the effects of combining of PAT-DX1 with standard of care radiation therapy in HGG, one of the hardest to treat forms of cancer, and particularly exciting that 2 of the 10 animals treated were long term survivors. These impressive results offer the potential for future clinical strategies that allow the reduction of radiation dose and its associated side effects, particularly in children. We are excited to be working with Patrys as we work to optimize strategies for combining standard of care with PAT-DX1 therapies.”